Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder
ConclusionsFlexibly adding on a second antimuscarinic agent is effective and safe for only some OAB patients dissatisfied with the first antimuscarinic treatment in the short‐term period. The patients' dropout rate is high and the long‐term efficacy of the combination of two antimuscarinic agents is limited.
Publication date: Available online 19 November 2019Source: Case Reports in Women's HealthAuthor(s): Dudley Robinson, George AraklitisAbstractAnticholinergic medication remains integral in the management of women with Overactive Bladder syndrome although there is increasing evidence to support a link with the impairment of cognitive function. This editorial will review the available evidence and discuss the management of patients in order to minimise anticholinergic burden with a particular focus on the elderly.
For 22 years, the world's largest pure-play medical device company was the only player in sacral neuromodulation, a space that addresses urinary problems as well as fecal incontinence. Now there'sÂ a new kid on the block, which has created quite an intense David vs. GoliathÂ medtech story. For those unfamiliar with the Axonics vs. Medtronic story up to this point, click here forÂ a quick rundown of recent events that have transpired in this market. Â FDA Approves Second Indication for Axonics r-SNM FDA approved the urinary indications for an implantable rechargeable sacral neuro...
Publication date: Available online 17 November 2019Source: European UrologyAuthor(s): Tom Marcelissen, Kevin Rademakers
In conclusion, limited evidence shows that routine urodynamics prior to non-surgical management of UI or surgical management of SUI is not associated with improved treatment outcomes, when compared to clinical evaluation only. Well-designed clinical trials are needed to evaluate the clinical and cost-effectiveness of routine urodynamics prior to surgical management of SUI and OAB.
ConclusionsMirabegron efficacy, safety, and tolerability over 12 wk were confirmed in patients aged ≥65 yr with OAB and incontinence.Patient summaryWe examined the effect of mirabegron compared with placebo in people aged 65 yr or older with overactive bladder and incontinence. Mirabegron improved the symptoms of overactive bladder compared with placebo. Side effects were similar to those already known for mirabegron.
Review in-depth clinical information, latest medical news, and guidelines on urinary incontinence, urge incontinence, and adult incontinence. Read about overactive bladder (OAB) and overactive bladder treatment.
AbstractPurpose of ReviewNocturia is defined as awakening due to the desire to void during a period of intended sleep. The pathophysiology of nocturia is multifactorial and management remains a challenge. Herein, we provide an overview of the management strategies for nocturia and summarize the existing evidence for treatment of nocturia across the condition ’s broad etiologic categories: nocturnal polyuria, diminished bladder capacity, and global polyuria.Recent FindingsTreatment should begin with behavioral modification. A high level of evidence supports the efficacy of desmopressin in the treatment of nocturnal po...
In conclusion, significant in vitro permeability and in vivo absorption of Sol from the transdermal formulations were observed. PMID: 31685750 [PubMed - in process]
Authors: Tae BS, Park TY, Jeon BJ, Chung H, Lee YH, Park JY, Bae JH, Choi H Abstract Purpose: To evaluate seasonal variations of overactive bladder (OAB) symptoms in women who visited hospital clinics. Methods: Medical records of female patients treated for OAB symptoms from January 2011 to December 2017 were retrospectively reviewed. Patients with pyuria at the first visit, those who did not complete the questionnaire, and those with